Hoth Therapeutics Stock Price, News & Analysis (NASDAQ:HOTH) $1.14 +0.04 (+3.64%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$1.11▼$1.1550-Day Range$1.03▼$1.7552-Week Range$0.99▼$12.50Volume37,261 shsAverage Volume808,532 shsMarket Capitalization$4.95 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Hoth Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside733.3% Upside$9.50 Price TargetShort InterestHealthy0.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.87Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 stars 3.5 Analyst's Opinion Consensus RatingHoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Hoth Therapeutics has a forecasted upside of 733.3% from its current price of $1.14.Amount of Analyst CoverageHoth Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.69% of the float of Hoth Therapeutics has been sold short.Short Interest Ratio / Days to CoverHoth Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hoth Therapeutics has recently increased by 19.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHoth Therapeutics does not currently pay a dividend.Dividend GrowthHoth Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOTH. Previous Next 3.8 News and Social Media Coverage News SentimentHoth Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Hoth Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for HOTH on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hoth Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.29% of the stock of Hoth Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 2.17% of the stock of Hoth Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Hoth Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hoth Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHoth Therapeutics has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Hoth Therapeutics Stock (NASDAQ:HOTH)Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Read More HOTH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HOTH Stock News HeadlinesNovember 14, 2023 | markets.businessinsider.comHoth Completes Pre-IND Meeting With FDA On Development Of HT-KIT TherapeuticNovember 14, 2023 | finance.yahoo.comHoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KITNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 10, 2023 | finance.yahoo.comHoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023October 5, 2023 | finance.yahoo.comHoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug DiscoveryOctober 2, 2023 | markets.businessinsider.comHoth Therapeutics: FDA Grants Pre-IND Meeting For HT-KIT; Stock SurgesOctober 2, 2023 | finance.yahoo.comFDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer PatientsSeptember 15, 2023 | nasdaq.comEF Hutton Maintains Hoth Therapeutics (HOTH) Buy RecommendationNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comSeptember 15, 2023 | finance.yahoo.comHoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesSeptember 13, 2023 | markets.businessinsider.comHoth Therapeutics Reports Positive Preclinical Results Of HT-KIT Therapeutic; Stock SurgesSeptember 13, 2023 | marketwatch.comHoth Therapeutics Shares Rise 7% After Positive Study Data for HT-KITSeptember 13, 2023 | msn.comHoth stock tumbles on $2.9M direct offering, private placementSeptember 13, 2023 | marketwatch.comHoth Therapeutics Shares Drop 23% After Direct Offering PricesSeptember 13, 2023 | msn.comHoth Therapeutics' Investigational Cancer Drug Shows Encouraging Preclinical Activity In Stomach CancersSeptember 13, 2023 | finance.yahoo.comHoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid LeukemiaSeptember 13, 2023 | finance.yahoo.comHoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesSeptember 11, 2023 | markets.businessinsider.comHoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDASeptember 11, 2023 | finance.yahoo.comHoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer PatientsSeptember 6, 2023 | markets.businessinsider.comHoth Therapeutics Reports Positive Results From Phase 1b Trial Of BioLexaSeptember 6, 2023 | finance.yahoo.comHoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexaAugust 9, 2023 | msn.comHoth Therapeutics Alzheimer's Treatment Shows Improvement In Cognitive Function, AnxietyAugust 9, 2023 | finance.yahoo.comHoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's DiseaseJuly 19, 2023 | markets.businessinsider.comHoth Receives Protocol Approval For HT-001 Cancer Therapeutic; Stock UpJune 20, 2023 | markets.businessinsider.comBenchmark Co. Remains a Buy on Hoth Therapeutics (HOTH)June 20, 2023 | markets.businessinsider.comAnalyst Expectations for Hoth Therapeutics's FutureJune 20, 2023 | benzinga.comBenchmark Reiterates Speculative Buy on Hoth Therapeutics, Maintains $5 Price TargetSee More Headlines Receive HOTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HOTH CUSIPN/A CIK1711786 Webwww.hoththerapeutics.com Phone(646) 756-2997FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$9.50 High Stock Price Target$14.00 Low Stock Price Target$5.00 Potential Upside/Downside+733.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($4.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-102.79% Return on Assets-87.04% Debt Debt-to-Equity RatioN/A Current Ratio7.63 Quick Ratio7.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book0.32Miscellaneous Outstanding Shares4,346,000Free Float4,203,000Market Cap$4.95 million OptionableNot Optionable Beta0.58 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Robb Knie (Age 54)President, CEO & Chairman Comp: $844.01kMr. David S. Briones (Age 47)Chief Financial Officer Ms. Hayley SpringerExecutive Vice President of OperationsKey CompetitorsXenetic BiosciencesNASDAQ:XBIONabriva TherapeuticsNASDAQ:NBRVDMK PharmaceuticalsNASDAQ:DMKAddex TherapeuticsNASDAQ:ADXNAptinyxNASDAQ:APTXView All Competitors HOTH Stock Analysis - Frequently Asked Questions Should I buy or sell Hoth Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HOTH shares. View HOTH analyst ratings or view top-rated stocks. What is Hoth Therapeutics' stock price target for 2024? 2 equities research analysts have issued 1 year price targets for Hoth Therapeutics' shares. Their HOTH share price targets range from $5.00 to $14.00. On average, they predict the company's share price to reach $9.50 in the next year. This suggests a possible upside of 733.3% from the stock's current price. View analysts price targets for HOTH or view top-rated stocks among Wall Street analysts. How have HOTH shares performed in 2023? Hoth Therapeutics' stock was trading at $7.80 at the beginning of the year. Since then, HOTH shares have decreased by 85.4% and is now trading at $1.14. View the best growth stocks for 2023 here. Are investors shorting Hoth Therapeutics? Hoth Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 29,700 shares, an increase of 19.8% from the October 31st total of 24,800 shares. Based on an average daily trading volume, of 213,600 shares, the short-interest ratio is currently 0.1 days. Currently, 0.7% of the company's shares are sold short. View Hoth Therapeutics' Short Interest. When is Hoth Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our HOTH earnings forecast. How were Hoth Therapeutics' earnings last quarter? Hoth Therapeutics, Inc. (NASDAQ:HOTH) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($3.50) EPS for the quarter, missing analysts' consensus estimates of ($3.38) by $0.13. When did Hoth Therapeutics' stock split? Shares of Hoth Therapeutics reverse split before market open on Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Hoth Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu BioPharma (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV). When did Hoth Therapeutics IPO? (HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO. How do I buy shares of Hoth Therapeutics? Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:HOTH) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.